Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate with Clinical Benefit

An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer, according to three-year follow-up results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.

Login Or Register To Read Full Story